{"denoms":[{"counts":[{"groupId":"BG000","value":"1086"}],"units":"Participants"}],"groups":[{"description":"This was a retrospective sample analysis representative for practices and hospitals in Germany. The treatments and infection data were collected from patients with chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM). GL adherence (GLAD) was analysed.","id":"BG000","title":"Non-interventional Retrospective Observational Study."}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"267"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"819"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"33","upperLimit":"93","value":"73"}]}]}],"description":"Age at the start of the therapy line under investigation","dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"475"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"611"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1086"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1086"}]}],"title":"Germany"}],"description":"This was a retrospective sample analysis of patients from practices and hospitals in Germany who were representatively screened using previously collected care parameters of the participating institutions. Previous and current treatment and infection data were collected from patients who received a line of therapy for the treatment of CLL or MM started in 2018 (1st, 2nd and 3rd or higher line). The time period was chosen to ensure that patients have been followed up for at least 12 months in order to collect data on susceptibility to infection and possible secondary immunodeficiencies.","paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"539"}],"title":"1st line"},{"measurements":[{"groupId":"BG000","value":"317"}],"title":"2nd line"},{"measurements":[{"groupId":"BG000","value":"230"}],"title":"3rd line"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Therapy Line","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"490"}],"title":"Chronic Lymphocytic Leukaemia (CLL)"},{"measurements":[{"groupId":"BG000","value":"596"}],"title":"Multiple Myeloma (MM)"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Disease","unitOfMeasure":"Participants"}],"populationDescription":"Patients with chronic lymphocytic leukaemia and multiple myeloma and systemic treatment in 2018"}